Annual Cash & Cash Equivalents
$246.99 M
+$98.18 M+65.98%
December 31, 2023
Summary
- As of February 8, 2025, FOLD annual cash & cash equivalents is $246.99 million, with the most recent change of +$98.18 million (+65.98%) on December 31, 2023.
- During the last 3 years, FOLD annual cash & cash equivalents has risen by +$83.75 million (+51.31%).
- FOLD annual cash & cash equivalents is now at all-time high.
Performance
FOLD Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$233.65 M
+$24.31 M+11.61%
September 30, 2024
Summary
- As of February 8, 2025, FOLD quarterly cash and cash equivalents is $233.65 million, with the most recent change of +$24.31 million (+11.61%) on September 30, 2024.
- Over the past year, FOLD quarterly cash and cash equivalents has dropped by -$29.67 million (-11.27%).
- FOLD quarterly cash and cash equivalents is now -39.45% below its all-time high of $385.90 million, reached on September 30, 2021.
Performance
FOLD Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
FOLD Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +66.0% | -11.3% |
| 3 y3 years | +51.3% | -11.3% |
| 5 y5 years | +209.7% | -11.3% |
FOLD Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +66.0% | -15.8% | +57.0% |
| 5 y | 5-year | at high | +72.9% | -39.5% | +89.6% |
| alltime | all time | at high | +3729.8% | -39.5% | +3522.9% |
Amicus Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $233.65 M(+11.6%) |
| Jun 2024 | - | $209.34 M(-0.2%) |
| Mar 2024 | - | $209.76 M(-15.1%) |
| Dec 2023 | $246.99 M(+66.0%) | $246.99 M(-6.2%) |
| Sep 2023 | - | $263.32 M(+24.6%) |
| Jun 2023 | - | $211.31 M(+31.6%) |
| Mar 2023 | - | $160.60 M(+7.9%) |
| Dec 2022 | $148.81 M(-39.3%) | $148.81 M(-46.4%) |
| Sep 2022 | - | $277.59 M(+17.8%) |
| Jun 2022 | - | $235.64 M(+1.0%) |
| Mar 2022 | - | $233.32 M(-4.8%) |
| Dec 2021 | $245.20 M(+50.2%) | $245.20 M(-36.5%) |
| Sep 2021 | - | $385.90 M(+118.6%) |
| Jun 2021 | - | $176.54 M(-4.5%) |
| Mar 2021 | - | $184.83 M(+13.2%) |
| Dec 2020 | $163.24 M(+14.3%) | $163.24 M(-22.5%) |
| Sep 2020 | - | $210.63 M(+28.0%) |
| Jun 2020 | - | $164.57 M(+33.5%) |
| Mar 2020 | - | $123.23 M(-13.7%) |
| Dec 2019 | $142.84 M(+79.1%) | $142.84 M(-14.1%) |
| Sep 2019 | - | $166.32 M(-24.6%) |
| Jun 2019 | - | $220.58 M(+128.9%) |
| Mar 2019 | - | $96.35 M(+20.8%) |
| Dec 2018 | $79.75 M(+62.6%) | $79.75 M(-60.5%) |
| Sep 2018 | - | $201.83 M(+175.3%) |
| Jun 2018 | - | $73.31 M(-35.9%) |
| Mar 2018 | - | $114.32 M(+133.0%) |
| Dec 2017 | $49.06 M(-73.8%) | $49.06 M(-23.5%) |
| Sep 2017 | - | $64.13 M(+71.5%) |
| Jun 2017 | - | $37.39 M(-16.4%) |
| Mar 2017 | - | $44.76 M(-76.1%) |
| Dec 2016 | $187.03 M(+169.2%) | $187.03 M(+464.8%) |
| Sep 2016 | - | $33.12 M(-48.0%) |
| Jun 2016 | - | $63.66 M(+170.8%) |
| Mar 2016 | - | $23.51 M(-66.2%) |
| Dec 2015 | $69.48 M | $69.48 M(+257.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2015 | - | $19.44 M(-92.2%) |
| Jun 2015 | - | $249.02 M(+763.9%) |
| Mar 2015 | - | $28.83 M(+19.7%) |
| Dec 2014 | $24.07 M(-44.8%) | $24.07 M(+22.4%) |
| Sep 2014 | - | $19.67 M(-53.1%) |
| Jun 2014 | - | $41.90 M(+52.2%) |
| Mar 2014 | - | $27.53 M(-36.9%) |
| Dec 2013 | $43.64 M(+28.5%) | $43.64 M(+45.2%) |
| Sep 2013 | - | $30.05 M(+28.0%) |
| Jun 2013 | - | $23.48 M(-12.2%) |
| Mar 2013 | - | $26.74 M(-21.3%) |
| Dec 2012 | $33.97 M(+32.3%) | $33.97 M(+40.0%) |
| Sep 2012 | - | $24.27 M(-15.9%) |
| Jun 2012 | - | $28.86 M(+17.7%) |
| Mar 2012 | - | $24.52 M(-4.5%) |
| Dec 2011 | $25.67 M(-13.2%) | $25.67 M(+12.5%) |
| Sep 2011 | - | $22.81 M(-11.6%) |
| Jun 2011 | - | $25.79 M(-6.8%) |
| Mar 2011 | - | $27.66 M(-6.5%) |
| Dec 2010 | $29.57 M(+52.9%) | $29.57 M(+33.8%) |
| Sep 2010 | - | $22.10 M(-10.3%) |
| Jun 2010 | - | $24.62 M(-26.6%) |
| Mar 2010 | - | $33.56 M(+73.5%) |
| Dec 2009 | $19.34 M(-31.1%) | $19.34 M(-5.6%) |
| Sep 2009 | - | $20.49 M(+30.0%) |
| Jun 2009 | - | $15.76 M(-32.2%) |
| Mar 2009 | - | $23.24 M(-17.2%) |
| Dec 2008 | $28.07 M(-36.5%) | $28.07 M(+41.4%) |
| Sep 2008 | - | $19.86 M(+61.2%) |
| Jun 2008 | - | $12.31 M(-32.3%) |
| Mar 2008 | - | $18.20 M(-58.8%) |
| Dec 2007 | $44.19 M(+264.4%) | $44.19 M(+121.7%) |
| Sep 2007 | - | $19.93 M(-24.8%) |
| Jun 2007 | - | $26.49 M(+33.5%) |
| Mar 2007 | - | $19.85 M(+63.7%) |
| Dec 2006 | $12.13 M(+88.0%) | $12.13 M(+88.0%) |
| Dec 2005 | $6.45 M | $6.45 M |
FAQ
- What is Amicus Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Amicus Therapeutics?
- What is Amicus Therapeutics annual cash & cash equivalents year-on-year change?
- What is Amicus Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Amicus Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of FOLD is $246.99 M
What is the all time high annual cash & cash equivalents for Amicus Therapeutics?
Amicus Therapeutics all-time high annual cash & cash equivalents is $246.99 M
What is Amicus Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, FOLD annual cash & cash equivalents has changed by +$98.18 M (+65.98%)
What is Amicus Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of FOLD is $233.65 M
What is the all time high quarterly cash and cash equivalents for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly cash and cash equivalents is $385.90 M
What is Amicus Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, FOLD quarterly cash and cash equivalents has changed by -$29.67 M (-11.27%)